Evidence map›Paper›PMID 40210099›Full record

ArticleToxicology and applied pharmacology2025

Estimation of species- and sex-specific PFAS pharmacokinetics in mice, rats, and non-human primates using a Bayesian hierarchical methodology.

Todd J Zurlinden, Michael W Dzierlenga, Dustin F Kapraun, Caroline Ring, Amanda S Bernstein, Paul M Schlosser, Viktor Morozov

Abstract read
In one paragraph

Article in Toxicology and applied pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Todd J ZurlindenU.S. Environmental Protection Agency, Office of Research and Development, Center for Public Health and Environmental Assessment, USA. Electronic address: zurlinden.todd@epa.gov.
Michael W DzierlengaU.S. Environmental Protection Agency, Office of Research and Development, Center for Public Health and Environmental Assessment, USA.
Dustin F KapraunU.S. Environmental Protection Agency, Office of Research and Development, Center for Public Health and Environmental Assessment, USA.
Caroline RingU.S. Environmental Protection Agency, Office of Research and Development, Center for Computational Toxicology and Exposure, USA.
Amanda S BernsteinU.S. Environmental Protection Agency, Office of Research and Development, Center for Public Health and Environmental Assessment, USA; Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA.
Paul M SchlosserU.S. Environmental Protection Agency, Office of Research and Development, Center for Public Health and Environmental Assessment, USA.
Viktor MorozovU.S. Environmental Protection Agency, Office of Research and Development, Center for Public Health and Environmental Assessment, USA.

Funding

Intramural EPA EPA999999
6 · The paper itself

Abstract

The carbon chain length, degree of fluorination, and functional group of per- and polyfluoroalkyl substances (PFAS) influences the bioaccumulation and half-lives of these substances in humans and laboratory animals. Pharmacokinetic (PK) studies using laboratory animals characterize the absorption, distribution, metabolism, and excretion (ADME) of a PFAS and can provide the underlying data for inter-species extrapolation to inform human pharmacokinetics. However, variations in ADME arise due to differences in protein binding and renal and hepatobiliary clearance mechanisms. In particular, sex- and species-specific differences in active transporter abundance and PFAS binding affinity challenge body weight-based extrapolation assumptions from animal models to human PK parameters. Because these protein-dependent changes in ADME do not always scale with species body weight, classic allometric scaling assumptions can fail to account for species-specific transporter-mediated clearance. In addition, study-dependent differences in pharmacokinetic modeling approaches and parameterization techniques can result in large differences among the PK parameters reported in the literature. To better quantify PFAS pharmacokinetics and characterize the underlying uncertainty, we implemented a Bayesian inference hierarchical model to estimate PFAS PK parameters for multiple species (mice, rats, and non-human primates) using numerous single-dose animal studies. Through an alternative parameterization of the one- and two-compartment models, this method improved parameter identifiability and allowed for the use of prior information on PFAS absorption rate, clearance, and volume of distribution. Using reported time-course concentration data, we estimated sex-specific clearance, volume of distribution, and half-life across mice, rats, and non-human primates using a consistent modeling methodology for eight PFAS: PFHxA, PFHxS, PFNA, PFDA, PFBS, PFBA, PFOA, and PFOS. The resulting comparison to available human data demonstrated that standard volume of distribution body-mass scaling (BW

Indexed as

Environmental PollutantsFluorocarbonsAnimalsBayes TheoremFemaleMacaca fascicularisMaleMiceModels, BiologicalRatsRats, Sprague-DawleySex FactorsSpecies SpecificityTissue DistributionEnvironmental PollutantsFluorocarbonsAllometric scalingBayesian hierarchicalInter-species extrapolationPer- and polyfluoroalkyl substances (PFAS)Pharmacokinetic modelsPharmacokinetic uncertainty

Identifiers

PMID40210099
PMCPMC12172007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.